Infant postnatal prophylaxis following maternal viraemia during breastfeeding

Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1–2 trial

(2022) Theodore D Ruel et al.   Lancet HIV

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

(2022) Pauline Amuge et al.   Lancet HIV

Over a third of childbearing women with HIV would like to breastfeed: A UK survey of women living with HIV

(2021) Farai Nyatsanza et al.   INTERNATIONAL JOURNAL OF STD & AIDS

Emergent resistance to dolutegravir among INSTI-naive patients on first-line or second-line antiretroviral therapy: a review of published cases

(2020) Muge Cevik et al.   Open Forum Infectious Diseases

“In the United States, we say, ‘No breastfeeding,’ but that is no longer realistic” : provider perspectives towards infant feeding among women living with HIV in the United States

(2019) Emily L Tuthill et al.   Journal of the International AIDS Society

Virtual support for paediatric HIV treatment decision making

(2014) Kirsty Le Doare et al.   ARCHIVES OF DISEASE IN CHILDHOOD